Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• the present invention relates to new imidazo [1,3,5] triazinones, processes for their preparation and their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
• the compounds according to the invention are potent inhibitors of cyclic guanosine 3 ', 5'-monophophate metabolizing phosphodiesterases (cGMP - PDE's). According to the nomenclature of Beavo and Reifsnyder (Trends in Pharmacol. Sci. 11, 150-155, 1990), the phosphodiesterase isoenzymes PDE-I, PDE-II and PDE-V are concerned.
• An increase in the cGMP concentration can lead to curative, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilating, natriuretic and diuretic effects. It can be the short or long term modulation of vascular and cardiac inotropy, affect the heart rhythm and cardiac conduction (JC Stoclet, T. Keravis, N. Komas and C. Kugnier, Exp. Opin. luvest. Drugs (1995), 4 (11), 1081-1100) , The inhibition of the cGMP-PDE's can also lead to an enhancement of the erection. Such compounds are therefore suitable for the treatment of erectile dysfunction.
• the present invention now relates to new imidazo [1,3,5] triazinones of the general formula (I)
• R 1 represents straight-chain or branched alkyl having up to 4 carbon atoms
• R represents straight-chain or branched alkyl having up to 4 carbon atoms or (C 3 -C 8 ) cycloalkyl
• R 3 represents hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms
• R 4 and R 5 are the same or different and stand for hydrogen, (C] -C 6 ) alkoxy, hydroxy or for (C 1 -C 8 ) alkyl, which may be up to 3 times the same or different Hydroxy, (-C ⁇ alkoxy or by residues of the formulas
• R 6 and R 7 are identical or different and are hydrogen or (Cf-C 6 ) -alkyl
• (C 1 -C 8) alkyl is optionally substituted by phenyl or phenoxy, which in turn is optionally one to three times, identical or different, by halogen, hydroxy, (C 1 -C 6 ) alkoxy, (dC ⁇ - Alkyl or substituted by a radical of the formula -SO 2 NR 8 R 9 ,
• R and R are identical or different and denote hydrogen or (Ci-C 6 ) alkyl
• R represents hydrogen or methyl
• R, 10 "and J R> 11 are the same or different and are hydrogen or (-) - alkyl
• R 12 and R 13 are identical or different and are hydrogen or (C C ⁇ ) alkyl
• R 14 and R 15 are identical or different and denote hydroxy, hydrogen or (CrG ⁇ alkyl, which is optionally substituted by hydroxy,
• R, 14 means hydrogen
• R 15 is a radical of the formula
• R 16 is hydrogen or (-CC 6 ) alkyl, optionally by
• Hydroxy is substituted, or a 5- to 6-membered aromatic heterocycle having up to 3 heteroatoms from the series S, N and / or O means
• the compounds of the invention can be in stereoisomeric forms, which are either like image and mirror image (enantiomers), or which are not like image and
• the invention relates to both the enantiomers or diastereomers or their respective mixtures.
• the racem Like the diastereomers, shapes can be separated into the stereoisomerically uniform constituents in a known manner.
• the substances according to the invention can also be present as salts.
• physiologically acceptable salts are preferred.
• Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids.
• Salts with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid are preferred , Phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.
• Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention.
• Sodium, potassium, magnesium or calcium salts and also ammonium salts derived from ammonia, or organic amines, such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, Ethylenediamine or 2-phenylethylamine.
• Cycloalkyl stands for cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, cycloheptyl or cyclooctyl. The following may preferably be mentioned: cyclopropyl, cyclopentyl and cyclohexyl.
• (C j -Cg) alkyl, (C t -CgV alkyl or (C 1 -C) alkyl represents a straight-chain or branched alkyl radical having 1 to 8, 1 to 6 or 1 to 4 carbon atoms. Examples include: methyl , Ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl and n-hexyl.
• a straight-chain or branched alkyl radical having 1 to 4 carbon atoms is preferred.
• a straight-chain or branched alkyl radical is particularly preferred with 1 to 3 carbon atoms.
• CC ⁇ -alkoxy stands for a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms. Examples include: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy and n-hexoxy
• a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms is preferred, and a straight-chain or branched alkoxy radical having 1 to 3 carbon atoms is particularly preferred.
• Halogen generally represents fluorine, chlorine, bromine and iodine. Fluorine, chlorine and bromine are preferred. Fluorine and chlorine are particularly preferred.
• a 5- to 6-membered aromatic heterocycle with up to 3 heteroatoms from the series S, O and or N is, for example, pyridyl, pyrimidyl, pyridazinyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl or imidazolyl.
• Pyridyl, pyrimidyl, pyridazinyl, furyl and thienyl are preferred.
• R 1 represents methyl or ethyl
• R 2 represents straight-chain or branched alkyl having up to 3 carbon atoms or (C 3 -C 6 ) cycloalkyl
• R 3 represents straight-chain or branched alkyl having up to 3 carbon atoms
• R 4 and R 5 are identical or different and represent hydrogen, (Ci-C) -alkoxy, hydroxy or (C 1 -C 7 ) -alkyl, which may be up to 3 times, the same or different, by hydroxy, (-C ⁇ alkoxy or by residues of the formulas
• R and R are identical or different and are hydrogen or methyl
• (CrC) -alkyl is optionally substituted by phenyl or phenoxy, which in turn is optionally one to three times, identical or different, by fluorine, chlorine, hydroxy, (-C-C 4 ) -alkoxy, (-C-C 4 ) -
• R> 4 represents hydrogen or methyl
• R 10 and R 11 are the same or different and are hydrogen or methyl
• R 12 and R 13 are the same or different and are hydrogen or methyl
• R 14 and R 15 are identical or different and denote hydroxy, hydrogen or (C 1 -C 3 ) -alkyl, which is optionally substituted by hydroxy, or
• R .14 means hydrogen
• R 15 is a radical of the formula
• R 16 is hydrogen or (CC 5 ) alkyl, which is optionally substituted by hydroxy, or is pyridyl, pyrimidyl, furyl, pyrryl or thienyl
• R 1 represents methyl or ethyl
• R represents n-propyl or cyclopentyl
• R 3 represents methyl, ethyl or n-propyl
• R 4 and R 5 are the same or different and represent hydrogen, (C 1 -C 3 ) alkoxy, hydroxy or (C 1 -C 6 ) alkyl, which may be up to 3 times the same or different Hydroxy, (C 1 -C 3 ) alkoxy or by residues of the formulas
• R 6 and R 7 are the same or different and are hydrogen or methyl
• C 1 -C 6 alkyl is optionally substituted by phenyl or phenoxy, which in turn is optionally substituted one to three times, identically or differently, by fluorine, hydroxyl, methoxy or by a radical of the formula —SO 2 NH 2 are,
• R> 4 represents hydrogen or methyl
• R 10 and R ⁇ are identical or different and are hydrogen or methyl
• R 12 and R 13 are methyl
• R 14 and R 15 are identical or different and denote hydroxy, hydrogen or a radical of the formula - (CH 2 ) 2 -OH,
• R. 14 means hydrogen
• R 15 is a radical of the formula
• R 16 is hydrogen, pyrimidyl or a radical of the formula - (CH 2 ) 2 -OH
• R 1 , R 2 and R 3 have the meaning given above,
• organic solvents which do not change under the reaction conditions are suitable as solvents for the individual steps.
• solvents preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethane, trichlorethylene or chlorobenzene Dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the solvents mentioned.
• the reaction temperatures can generally vary within a substantial range. Generally one works in a range from -20 ° C to 200 ° C, preferably from 0 ° C to 70 ° C.
• the process steps according to the invention are generally carried out at normal pressure. However, it is also possible to carry out overpressure or underpressure (e.g. in a range from 0.5 to 5 bar).
• the reactions can take place, for example, in a temperature range from 0 ° C. to room temperature and at normal pressure.
• R 1 has the meaning given above, in the NaOC 2 H 5 / C 2 H 5 OH system with compounds of the general formula (VI)
• R 2 has the meaning given above
• R 1 , R 2 and R 3 have the meaning given above,
• HMDS hexamethyldisilazane
• TMSC1 chlorotrimethylsilane
• organic solvents which do not change under the reaction conditions are suitable as solvents for the individual steps.
• solvents preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethane, trichloroethylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene or chloro-methylene, or dichloro-ethylenes,
• the reaction temperatures can generally vary within a substantial range. Generally one works in a range from -20 ° C to 200 ° C, preferably from 0 ° C to 70 ° C.
• the process steps according to the invention are generally carried out at normal pressure. However, it is also possible to carry out at overpressure or at underpressure (e.g. in a range from 0.5 to 5 bar).
• the reactions can, for example, in a temperature range from 0 ° C to
• EDRF Endothelium derived relaxing factor
• ANP atrial natriuretic peptide
• the compounds of general formula (I) according to the invention are suitable for the prophylaxis and / or treatment of diseases in which an increase in the cGMP concentration is beneficial, i.e. Diseases related to cGMP-regulated processes (usually simply referred to as 'cGMP-related diseases'). These include cardiovascular diseases, diseases of the genitourinary system and cerebrovascular diseases.
• cardiac diseases in the context of the present invention includes diseases such as, for example, high blood pressure, neuronal hypertension, stable and unstable angina, peripheral and cardiac vascular diseases, arrhythmias, thromboembolic diseases and ischemia such as myocardial infarction, stroke, transistor and ischemic attacks, angina pectoris, peripheral
• Circulatory disorders prevention of restenosis after thrombolysis therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA) and bypass.
• PTA percutaneous transluminal angioplasty
• PTCA percutaneous transluminal coronary angioplasty
• the compounds of the general formula (I) according to the invention can also be of importance for cerebrovascular diseases. These include, for example, cerebral ischemia, stroke, reperfusion damage, brain trauma, edema, cerebral thrombosis, dementia and Alzheimer's disease.
• PDE phosphorus diesterases
• the cGMP-stimulable PDE II, the cGMP-inhibitable PDE III and the cAMP-specific PDE IV were isolated from either pig or bovine myocardium.
• the Ca 2+ -calmodulin stimulable PDE I was isolated from pig aorta, pig brain or preferably from bovine aorta.
• the c-GMP specific PDE V was obtained from pig small intestine, pig aorta, human platelets and preferably from bovine aorta.
• the purification was carried out by anion exchange chromatography on MonoQ R Pharmacia, essentially using the method of M. Hoey and Miles D. Houslay, Biochemical Pharmacology, Vol. 40, 193-202 (1990) and C.
• the enzyme activity is determined in a test batch of 100 ⁇ l in 20 mM Tris / HCl buffer pH 7.5 which contains 5 mM MgCl 2 , 0.1 mg / ml bovine serum albumin and either 800 Bq HcAMP or HcGMP.
• the final concentration of the corresponding nucleotides is 10 6 mol / 1.
• the reaction is started by adding the enzyme, the amount of enzyme is such that about 50% of the substrate is converted during the incubation period of 30 min.
• 3 HcAMP is used as substrate and 10 "6 mol / 1 unlabeled cGMP is added to the batch.
• the test was carried out according to the test protocol specified by the manufacturer.
• the [ 3 H] cAMP SPA assay was used to determine the activity of PDE II, with 10 "6 M cGMP being added to the reaction mixture to activate the enzyme has been.
• 10 "7 M cane product and 1 ⁇ M CaCl 2 were added to the reaction mixture.
• the PDE V was measured with the [ 3 H] cGMP SPA assay.
• the new active ingredients and their physiologically acceptable salts can be converted into the customary formulations in a known manner, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions , using inert, non-toxic, pharmaceutically acceptable carriers or solvents.
• the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. H. in amounts sufficient to achieve the dosage range indicated.
• the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, if appropriate using emulsifiers and / or dispersants, for example when used of water as a diluent, organic solvents can optionally be used as auxiliary solvents.
• the application is carried out in the usual way, preferably orally, transdermally or parenterally, e.g. perlingual, buccal, intravenous, nasal, rectal or inhalation.
• doses of 0.001 to 50 mg / kg are generally administered for oral administration.
• parenteral administration e.g. A dose of 0.001 mg / kg - 0.5 mg / kg is advisable via mucous membranes nasally, buccally, or by inhalation.
• the compounds according to the invention are also suitable for use in veterinary medicine.
• the compounds or their non-toxic salts can be administered in a suitable formulation in accordance with general veterinary practices.
• the veterinarian can determine the type of application and the dosage according to the type of animal to be treated.
• a hydrogen must always be added in structural formulas with one or more unsaturated valences on the nitrogen or oxygen atom.
• Structures e.g. B. with a structural element "-N-" actually means “-NH-” and structures z. B. with a structural element with "-O” actually means “- OH”.
• Standard instruction A implementation of amines with acidic functionalities
• Standard instruction B reaction of amines with neutral functionalities First 0.125 mmol amine are introduced and 0.03 mmol sulfonic acid chloride as a solution in 1,2-dichloroethane is pipetted in by the synthesizer. After 24 hours it will
• 0.05 mmol of amine are initially introduced and 0.038 mmol of sulfonic acid chloride as a solution in 1,2-dichloroethane and 0.05 mmol of triethylamine as a solution in 1,2-dichloroethane are pipetted in from the synthesizer. After 24 h, 3 ml of saturated NaHCO 3 solution are first added and the reaction mixture is filtered through a two-phase cartridge. After concentrating the filtrate in vacuo, this is obtained

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Neurosurgery (AREA)
• Urology & Nephrology (AREA)
• Reproductive Health (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Endocrinology (AREA)
• Hematology (AREA)
• Gynecology & Obstetrics (AREA)
• Diabetes (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Anesthesiology (AREA)
• Pregnancy & Childbirth (AREA)
• Vascular Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26004043

Family Applications (1)

Country Status (13)

Families Citing this family (30)

Family Cites Families (9)

• 2000
  • 2000-12-12 KR KR1020027008156A patent/KR20020062770A/ko not_active Application Discontinuation
  • 2000-12-12 JP JP2001549398A patent/JP2003519150A/ja not_active Withdrawn
  • 2000-12-12 CN CN00818969A patent/CN1434825A/zh active Pending
  • 2000-12-12 TR TR2002/01638T patent/TR200201638T2/xx unknown
  • 2000-12-12 AU AU28420/01A patent/AU781028B2/en not_active Ceased
  • 2000-12-12 CA CA002395548A patent/CA2395548A1/en not_active Abandoned
  • 2000-12-12 WO PCT/EP2000/012597 patent/WO2001047928A2/de active IP Right Grant
  • 2000-12-12 IL IL15002200A patent/IL150022A0/xx unknown
  • 2000-12-12 PL PL00356848A patent/PL356848A1/xx not_active Application Discontinuation
  • 2000-12-12 BR BR0017043-7A patent/BR0017043A/pt not_active IP Right Cessation
  • 2000-12-12 MX MXPA02006240A patent/MXPA02006240A/es active IP Right Grant
  • 2000-12-12 US US10/168,194 patent/US6803365B2/en not_active Expired - Fee Related
  • 2000-12-12 EP EP00993611A patent/EP1244673A2/de not_active Withdrawn
• 2004
  • 2004-07-15 US US10/892,984 patent/US7091203B2/en not_active Expired - Fee Related

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events